BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33844533)

  • 1. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Poli G; Alberti M; Passoni A; Gaidano V; Pippione AC; Vitale N; Bonanni D; Rolando B; Cignetti A; Ramondetti C; Lanno A; Ferraris DM; Canepa B; Buccinnà B; Piccinini M; Rizzi M; Saglio G; Al-Karadaghi S; Boschi D; Miggiano R; Tuccinardi T; Lolli ML
    J Med Chem; 2022 Oct; 65(19):12701-12724. PubMed ID: 36162075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
    Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
    DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
    Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
    Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifunctional Naphtho[2,3-
    Zuo Z; Liu X; Qian X; Zeng T; Sang N; Liu H; Zhou Y; Tao L; Zhou X; Su N; Yu Y; Chen Q; Luo Y; Zhao Y
    J Med Chem; 2020 Jul; 63(14):7633-7652. PubMed ID: 32496056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
    Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
    Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
    Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
    Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
    Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
    J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
    Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
    Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors.
    Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P
    Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase.
    Zeng F; Quan L; Yang G; Qi T; Zhang L; Li S; Li H; Zhu L; Xu X
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31370178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
    Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
    Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
    Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
    Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking.
    Ren X; Liu X; Hua M; Dai Y; Ren X; Sui C; Li X; Jiang Z; Tian M; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14388. PubMed ID: 37926553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
    Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.